-
Continuous improvement of FEV1 in severe eosinophilic asthmatics on anti‐interleukin‐5 therapy Allergy (IF 12.4) Pub Date : 2024-04-25 Alain Michils, Jean‐Pierre Makhoul, Nathan Blekic, Amaryllis Haccuria, Silvia Perez‐Bogerd, Andreï Malinovschi, Alain Van Muylem
-
Clinical applicability of AI‐based prognosis prediction for a rare ocular surface disease Allergy (IF 12.4) Pub Date : 2024-04-25 Mayumi Ueta, Yasuhito Watanabe, Charles Melby‐Thompson, Chie Sotozono, Shigeru Kinoshita
-
Ambient pollen exposure and pollen allergy symptom severity in the EPOCHAL study Allergy (IF 12.4) Pub Date : 2024-04-25 Axel Luyten, Alexandra Bürgler, Sarah Glick, Marek Kwiatkowski, Regula Gehrig, Minaya Beigi, Karin Hartmann, Marloes Eeftens
BackgroundAmbient pollen exposure causes nasal, ocular, and pulmonary symptoms in allergic individuals, but the shape of the exposure–response association is not well characterized. We evaluated this association and determined (1) whether symptom severity differs between subpopulations; (2) how the association changes over the course of the pollen season; and (3) which pollen exposure time lags affect
-
Response of sputum periostin to anti‐T2 biologics treatment in severe asthma Allergy (IF 12.4) Pub Date : 2024-04-23 Parameswaran Nair, Katherine Radford, Satoshi Nunomura, Manali Mukherjee, Kenji Izuhara
-
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry Allergy (IF 12.4) Pub Date : 2024-04-23 Marek Niedoszytko, Aleksandra Gorska, Knut Brockow, Patrizia Bonadonna, Magdalena Lange, Hanneke Kluin‐Nelemans, Hanneke Oude‐Elberink, Vito Sabato, Khalid Shoumariyeh, Dagmar von Bubnoff, Sabine Müller, Anja Illerhaus, Michael Doubek, Irena Angelova‐Fischer, Olivier Hermine, Michel Arock, Chiara Elena, Luca Malcovati, Akif Selim Yavuz, Tanja Daniela Schug, Anna Belloni Fortina, Várkonyi Judit, Jason
BackgroundHypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry.MethodsData were collected
-
Oral immunotherapy in alpha‐gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management? Allergy (IF 12.4) Pub Date : 2024-04-20 D. Ünal, D. Eyice‐Karabacak, A. Kutlu, S. Demir, O. C. Tüzer, F. A. Arslan, S. R. Işık, A. Gelincik
-
Inhibition of RNase 7 by RNase inhibitor promotes inflammation and Staphylococcus aureus growth: Implications for atopic dermatitis Allergy (IF 12.4) Pub Date : 2024-04-20 Franziska Rademacher, Annika Scheel, Regine Gläser, Lena Schröder, Nina Heinemann, Joachim Bartels, Sascha Gerdes, Dora Stölzl, Elke Rodriguez, Katinka Döhner, Stephan Weidinger, Thomas Werfel, Jürgen Harder
BackgroundThe antimicrobial ribonuclease RNase 7 is abundantly expressed in the epidermis of lesional skin of atopic dermatitis (AD). Host RNase inhibitor (RI) binds to RNase 7 and blocks its ribonuclease activity. This study aimed to evaluate the impact of RNase 7–RI interactions on AD.MethodsCultured human primary keratinocytes, with siRNA‐mediated downregulation of RNase 7 and RI, were stimulated
-
Lin−CD117+CD34+FcεRI+ progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti‐IgE therapy Allergy (IF 12.4) Pub Date : 2024-04-18 Katie Ridge, Barry Moran, P. Abigail Alvarado‐Vazquez, Jenny Hallgren, Mark A. Little, Alan D. Irvine, Cliona O'Farrelly, Jean Dunne, Conor M. Finlay, Niall Conlon
BackgroundChronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage−CD34hiCD117int/hiFcεRI+ cells in blood have previously been shown to represent a mast cell precursor.MethodsWe enumerated
-
Sunflower seed allergy: Identification of novel 2S‐albumins as potential marker allergens Allergy (IF 12.4) Pub Date : 2024-04-15 J. Achour, M. Reche, T. Valbuena, C. Chapuis, B. Guillon, O. Galet, K. Adel‐Patient, H. Bernard, S. Hazebrouck
-
Long‐term follow‐up of neutrophil activation after severe‐to‐critical SARS‐CoV‐2 infection: A longitudinal study Allergy (IF 12.4) Pub Date : 2024-04-13 Simon Valentin, Veronique Regnault, Jean‐Louis Gueant, Bruno Ribeiro Baptista, Thery Abel, Patrick Lacolley, Frederic Schlemmer, Ari Chaouat, François Chabot, Rosa‐Maria Gueant‐Rodriguez
-
SM17, a new IL‐17RB‐targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis Allergy (IF 12.4) Pub Date : 2024-04-09 Lik Hang Lam, Weimin Li, Wai Chung Wu, Kai Cheung Chow, Wai Yin Dennis Au, Guolin Xu, Ge Wang, Xuchen Qian, Ka Man Ng, Shaik Abdullah Nawabjan, Muthu Iswarya Gandhi Sethuraman, Wai Yan Choi, Billy Kwok Chong Chow, Shui On Leung, Chin Wai Hui
-
Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients Allergy (IF 12.4) Pub Date : 2024-04-08 Marie‐Charlotte Brüggen, Stephan Traidl, Yasutaka Mitamura, Sarah Walsh, Lars E. French, Nicholas Gulati, Elizabeth Phillips, Emanual Maverakis, Saskia Ingen‐Housz‐Oro
CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare.
-
Preventive allergen immunotherapy with inhalant allergens in children Allergy (IF 12.4) Pub Date : 2024-04-08 Varsha Dwivedi, Sonja Kopanja, Klara Schmidthaler, Justyna Sieber, Christina Bannert, Zsolt Szépfalusi
The efficacy and safety of preventive allergen immunotherapy (pAIT) in children are currently under investigation. Here, we provide an overview of pAIT with respiratory allergens concerning the prevention of new sensitizations, allergic disease onset and progression as well as further immunomodulatory effects. Three databases were searched for clinical pAIT studies in children. Selected publications
-
AM‐301, a barrier‐forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial Allergy (IF 12.4) Pub Date : 2024-04-06 Sven Becker, Sachin Deshmukh, Ferdinandus De Looze, Veronica Francardo, Jessie Lee, Anthony McGirr, Zachary Nathan, Christopher Rook, Thomas Meyer
-
Prior respiratory syncytial viral infection contributes to severe COVID‐19 illness: A nationwide cohort study Allergy (IF 12.4) Pub Date : 2024-04-05 Hwan Jin Lee, Min Ji Kim, Jong Seung Kim, Yong Chul Lee, Jae Seok Jeong
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be a major threat to public health around the world.1 Recently, there has been a growing recognition of the influence that prior respiratory viral infections, such as influenza, have on the outcomes of COVID-19.2 However, little is known about the long-term effects of RSV infection
-
Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID‐exacerbated respiratory disease Allergy (IF 12.4) Pub Date : 2024-04-04 Franziska Hartung, Pascal Haimerl, Sonja Schindela, Veronika Mussack, Benedikt Kirchner, Fiona D. R. Henkel, Ulrike Bernhardt, Ulrich M. Zissler, Rachel Santarella‐Mellwig, Michael Pfaffl, Carsten B. Schmidt‐Weber, Adam M. Chaker, Julia Esser‐von Bieren
-
Patterns of allergen recognition in Ligustrum polysensitized patients: An immunoproteomics approach Allergy (IF 12.4) Pub Date : 2024-04-04 Raúl Porras‐Gutiérrez‐de‐Velasco, Blessy Maruthukunnel‐Mani, Juan Carlos Vizuet‐de‐Rueda, Josaphat Miguel Montero‐Vargas, Luis M. Teran
Members of the Oleaceae family, including Ligustrum (privet), Olea (olive), and Fraxinus (ash), are recognized as important causes of allergenic respiratory diseases worldwide. In Mexico City, nearly 37% of allergic patients have been reported to show sensitization to Ligustrum lucidum pollen, correlating with sensitization to Fraxinus, a very abundant tree in the city.1 Lig v 1, a homolog of Ole e
-
Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years Allergy (IF 12.4) Pub Date : 2024-04-02 Emma Guttman‐Yassky, Kenji Kabashima, Delphine Staumont‐Salle, Walter K. Nahm, Sylvia Pauser, Joel Correa Da Rosa, Britta Cathrina Martel, Daniel Elenius Madsen, Mads Røpke, Petra Arlert, Louise Steffensen, Andrew Blauvelt, Kristian Reich
-
EAACI guidelines on environmental science for allergy and asthma: The impact of short‐term exposure to outdoor air pollutants on asthma‐related outcomes and recommendations for mitigation measures Allergy (IF 12.4) Pub Date : 2024-04-02 Ioana Agache, Isabella Annesi‐Maesano, Lorenzo Cecchi, Benedetta Biagioni, Kian Fan Chung, Bernard Clot, Gennaro D'Amato, Athanasios Damialis, Stefano del Giacco, Javier Dominguez‐Ortega, Carmen Galàn, Stefanie Gilles, Stephen Holgate, Mohamed Jeebhay, Stelios Kazadzis, Kari Nadeau, Nikolaos Papadopoulos, Santiago Quirce, Joaquin Sastre, Fiona Tummon, Claudia Traidl‐Hoffmann, Jolanta Walusiak‐Skorupa
The EAACI Guidelines on the impact of short‐term exposure to outdoor pollutants on asthma‐related outcomes provide recommendations for prevention, patient care and mitigation in a framework supporting rational decisions for healthcare professionals and patients to individualize and improve asthma management and for policymakers and regulators as an evidence‐informed reference to help setting legally
-
Algorithms in allergy: Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria Allergy (IF 12.4) Pub Date : 2024-04-01 Allen P. Kaplan, Marta Ferrer
CONFLICT OF INTEREST STATEMENT Marta Ferrer has received honoraria (advisory board, speaker) from Novartis, Menarini, Uriach, FAES, Pfizer and MSD and has received a research Grant from GSK and Novartis.
-
-
IgE‐mediated allergic diseases are associated with Alzheimer's disease Allergy (IF 12.4) Pub Date : 2024-03-30 Andrzej Bozek, Magdalena Krupka‐Olek, Aleksandra Kawczyk Krupka
-
Patients' values and preferences for health states in allergic rhinitis—An artificial intelligence supported systematic review Allergy (IF 12.4) Pub Date : 2024-03-29 Jan Brozek, Ewa Borowiack, Ewelina Sadowska, Artur Nowak, Bernardo Sousa‐Pinto, Rafael José Vieira, Antonio Bognanni, Juan Jose Yepes Nuñez, Yuan Zhang, Torsten Zuberbier, Jean Bousquet, Holger J. Schünemann
BackgroundAllergic rhinitis (AR) impacts patients' physical and emotional well‐being. Assessing patients' values and preferences (V&P) related to AR is an essential part of patient‐centered care and of the guideline development process. We aimed to systematically summarize the information about patients' V&P on AR and its symptoms and impact on daily life.MethodsWe conducted systematic review in a
-
Environmental exposures drive the development of allergic diseases Allergy (IF 12.4) Pub Date : 2024-03-27 Luo Zhang, Cezmi A. Akdis
The global prevalence of allergic diseases, such as allergic rhinitis (AR) and asthma, has gradually increased since 1960s. AR prevalence has surged by 5%–25% across various regions in the past few decades.1 Similarly, the prevalence of asthma has progressively increased over the last 65 years in industrialized countries and 30–40 years in urbanized areas of low- and middle-level income countries,
-
Interleukin 31 transcription in a canine model of acute atopic dermatitis does not correlate with T‐cell infiltration Allergy (IF 12.4) Pub Date : 2024-03-27 Nicky Craig, Kim Ahrens, Rachel Wilkes, Tanja Opriessnig, Deborah V. Hoyle, Barry Bradford, Scott Maxwell, Jorge del Pozo, Maciej Parys, Takanori Kitamura, Rosanna Marsella
-
Mast cell activation identified through urine mediators Allergy (IF 12.4) Pub Date : 2024-03-27 Matthew P. Giannetti, Grace Godwin, Julia Middlesworth, Andrew Espeland, Jennifer Nicoloro‐SantaBarbara, Mariana Castells
-
Response to Correspondence to “Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy” Allergy (IF 12.4) Pub Date : 2024-03-25 P. J. de Kam, S. Zielen, J. A. Bernstein, U. Berger, M. Berger, M. Cuevas, D. Cypcar, A. Fuhr‐Horst, W. A. Greisner, M. Jandl, S. Laßmann, M. Worm, J. Matz, E. Sher, C. Smith, G. C. Steven, R. Mösges, M. H. Shamji, L. DuBuske, F. Borghese, K. Oluwayi, T. Zwingers, M. Seybold, O. Armfield, M. D. Heath, S. J. Hewings, M. F. Kramer, M. A. Skinner
-
Chicken meat allergy in children: Complex sensitization profiles with newly described allergen candidates Allergy (IF 12.4) Pub Date : 2024-03-25 T. Guiddir, H. Sénéchal, M. A. Selva, R. Couderc, I. Swoboda, C. Hilger, A. Kuehn, Y. Chantran, S. Yen‐Nicolaÿ, T. Vrai, G. Ruellou, B. Baudin, P. Poncet, A. Nemni
Chicken meat allergy (ChMA) has an estimated incidence of 0.6%–5%.1 Symptoms range from mild oral syndrome to systemic reactions. Individual sensitization profiles remain poorly understood. The objective was to exhaustively and individually explore the clinical parameters (Table 1) and the IgE repertoire of five children (P1 to P5, 6–12 years old) with primary ChMA, without egg allergy, in order to
-
Lupin, a potential “hidden” food anaphylaxis allergen: An alert from the Allergy‐Vigilance Network® Allergy (IF 12.4) Pub Date : 2024-03-22 Guillaume Pouessel, Dominique Sabouraud‐Leclerc, Pascale Beaumont, Amandine Divaret‐Chauveau, Eléna Bradatan, Pascale Dumond, Yasemin Karaca, Jean‐Marie Renaudin, Carine Metz‐Favre, Delphine Delalande, Anne‐Karine Correard, Sélina Tscheiller, Xavier Van der Brempt
Lupin is a legume considered as an emerging food allergen, but the true prevalence of lupin allergy is not known.1 Due to the increasing consumption of lupin and its potential cross-reactivity with peanut, the Allergy-Vigilance Network® (AVN) aimed to report lupin-induced anaphylaxis cases and compare their main characteristics to other foods (See Data S1 for Material and Methods). Of the 2708 cases
-
Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis Allergy (IF 12.4) Pub Date : 2024-03-14 Ibon Eguiluz‐Gracia, Rebecca V. Parkin, Janice A. Layhadi, Elizabeth Palmer, Xun Meng, Rongfei Zhu, Umit Sahiner, Stephen R. Durham, Maria Jose Torres, Cristobalina Mayorga, Carmen Rondon, Mohamed H. Shamji
-
High burden of clonal mast cell disorders and hereditary α‐tryptasemia in patients who need Hymenoptera venom immunotherapy Allergy (IF 12.4) Pub Date : 2024-03-13 Peter Korošec, Gunter J. Sturm, Jonathan J. Lyons, Tinkara Pirc Marolt, Manca Svetina, Mitja Košnik, Mihaela Zidarn, Mark Kačar, Nina Frelih, Nika Lalek, Ajda Demšar Luzar, Samo Zver, Matevž Škerget, Ewa Czarnobilska, Wojciech Dyga, Sanja Popović Grle, Miroslav Samarzija, Lisa Arzt‐Gradwohl, Urban Čerpes, Grzegorz Porebski, Branko Pevec, Eva Schadelbauer, Peter Kopač, Julij Šelb, Matija Rijavec
-
RNA‐sequencing of paired tape‐strips and skin biopsies in atopic dermatitis reveals key differences Allergy (IF 12.4) Pub Date : 2024-03-13 Blaine Fritz, Anne‐Sofie Halling, Isabel Díaz‐Pinés Cort, Maria Oberländer Christensen, Amalie Thorsti Møller Rønnstad, Caroline Meyer Olesen, Mette Hjorslev Knudgaard, Claus Zachariae, Steffen Heegaard, Jacob P. Thyssen, Thomas Bjarnsholt
-
Correction to Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics Allergy (IF 12.4) Pub Date : 2024-03-12
Citation: Lorente-Sorolla C, Bernaola J, Sánchez-Mellado D, Gil-Martínez M, Naharro-González S, Betancor D, Fernández-Nieto M, Pinillos-Robles EJ, Santillán Coello JM, Villacampa-Aubá JM, Rodríguez-Nieto MJ, Sastre J, Valverde-Monge M, Rodrigo-Muñoz JM, Del Pozo V. Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics. Allergy. 2023 Nov;78(11):3027-3031
-
Disparities in pediatric anaphylaxis triggers and management across Asia Allergy (IF 12.4) Pub Date : 2024-03-10 Agnes Sze Yin Leung, Elizabeth Huiwen Tham, Punchama Pacharn, Yuhan Xing, Hoang Kim Tu Trinh, Sooyoung Lee, Kangmo Ahn, Pantipa Chatchatee, Sakura Sato, Motohiro Ebisawa, Bee Wah Lee, Gary Wing Kin Wong
-
Reply to the correspondence on “Basophil activation test as predictor of severity and threshold of allergic reactions to egg” Allergy (IF 12.4) Pub Date : 2024-03-11 Alexandra F. Santos, Grammatiki Antoneria, Zainab Jama, Jana Ilangovan, Vikki Houghton
-
Prodromal symptoms of hereditary angioedema (HAE) attacks: A patient survey in UK and Spain Allergy (IF 12.4) Pub Date : 2024-03-11 Patrick F. K. Yong, Mar Guilarte
-
Neonatal skin dysbiosis to infantile atopic dermatitis: Mitigating effects of skin care Allergy (IF 12.4) Pub Date : 2024-03-09 Reika Aoyama, Seitaro Nakagawa, Yoko Ichikawa, Naohiro Inohara, Yuriko Yamazaki, Tomoka Ito, Takashi Sugihira, Michihiro Kono, Masashi Akiyama, Hiroki Takahashi, Akiko Takaya, Fumitaka Ichikawa, Taiji Nakano, Seiko Tanaka, Yutaka Koyano, Manabu Fujimoto, Gabriel Núñez, Naoki Shimojo, Yuumi Nakamura
Patients with atopic dermatitis (AD) harbor Staphylococcus aureus in lesional skin, causing dysbiosis, linked to disease flares and progression.1 The onset of dysbiosis-related AD during infancy remains unclear. To clarify this, we performed a longitudinal microbiome analysis in an interventional cohort study. In total, 177 infants, all of whom received skin care, were included in this study (Figure S1A
-
Legends of allergy and immunology: Kenji Izuhara Allergy (IF 12.4) Pub Date : 2024-03-08 Satoshi Nunomura, Kazunari Sugita, Kazuhiko Arima
CONFLICT OF INTEREST STATEMENT Satoshi Nunomura and Kazunari Sugita have no conflicts to declare, while Kazuhiko Arima is a full-time employee and stockholder of Sanofi K.K.
-
Type 1/17 CD103+CD4+ nasal‐resident memory T cells in non‐eosinophilic chronic rhinosinusitis with nasal polyps Allergy (IF 12.4) Pub Date : 2024-03-06 Min‐Seok Rha, Gyeongyeob Kim, Sol Lee, Chan Min Jung, Young‐Woo Lee, Hae Eun Noh, Yeonsu Jeong, Hyung‐Ju Cho, Chang‐Hoon Kim
-
Generation of a virus‐like particles based vaccine against IgE Allergy (IF 12.4) Pub Date : 2024-03-06 Zahra Gharailoo, Kevin Plattner, Gilles Augusto, Paul Engeroff, Monique Vogel, Martin F. Bachmann
BackgroundAnti‐IgE immunotherapy with monoclonal antibodies represents a breakthrough in treatment of severe allergic diseases. However, drawbacks such as short half‐life and high price are not negligible. Our objective is to develop an anti‐IgE vaccine based on virus‐like particles (VLPs) which can induce long‐lasting neutralizing IgG anti‐IgE antibodies reducing allergic responses without causing
-
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination Allergy (IF 12.4) Pub Date : 2024-03-04 Anika M. Valk, Jim B. D. Keijser, Koos P. J. van Dam, Eileen W. Stalman, Luuk Wieske, Maurice Steenhuis, Laura Y. L. Kummer, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Barbara Horváth, Dirk-Jan Hijnen, Corine R. G. Schreurs, Zoé L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Sofie Keijzer, Ninotska
-
Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases Allergy (IF 12.4) Pub Date : 2024-03-05 Roberto Berni Canani, Marco Caminati, Laura Carucci, Ibon Eguiluz‐Gracia
The epithelial barriers of the skin, gut, and respiratory tract are critical interfaces between the environment and the host, and they orchestrate both homeostatic and pathogenic immune responses. The mechanisms underlying epithelial barrier dysfunction in allergic and inflammatory conditions, such as atopic dermatitis, food allergy, eosinophilic oesophagitis, allergic rhinitis, chronic rhinosinusitis
-
Efficacy and safety of topical Streptococcus postbiotic emollient in adolescents and adults with mild‐to‐moderate atopic dermatitis: A randomized, double‐blind, vehicle‐controlled trial Allergy (IF 12.4) Pub Date : 2024-03-04 Min Seo Kim, Hyeon Jin Kim, So Min Kang, Young Mok Heo, Jiseung Kang, Tae Kyeong Ryu, Hyun Jeong Kim, Young‐Bong Choi, Sol Kim, Youn Hwa Nho, Seunghyun Kang, Lee Smith, Ai Koyanagi, Nikolaos G. Papadopoulos, Hyungwoo Jo, Dong‐Geol Lee, Jung U Shin, Dong Keon Yon
-
Climate crisis paralysis: Accelerating global action for health resilience in a changing world Allergy (IF 12.4) Pub Date : 2024-03-04 Jürgen Orasche, Kari C. Nadeau, Antonia Schuster, Johan Rockström, Cezmi A. Akdis, Claudia Traidl‐Hoffmann
1 CALLS FOR IMMEDIATE ACTION ARE GETTING LOUDER, BUT THEY ARE NOT HAVING A LASTING IMPACT ON SOCIETY AND POLITICAL INSTITUTIONS AS A WHOLE The global action on climate change is out of sync. The world is rapidly moving deeper into a dangerous climate crisis; science is providing ample warnings of an imminent planetary emergency; while policy and the global economy moves, at best, in incremental steps
-
Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study ‘COMFA’ Allergy (IF 12.4) Pub Date : 2024-03-03 Anastasia Demidova, Karl Philipp Drewitz, Parisut Kimkool, Nikolina Banjanin, Vladyslava Barzylovich, Erna Botjes, India Capper, Mary Anne R. Castor, Pasquale Comberiati, Emma E. Cook, Joana Costa, Derek K. Chu, Michelle M. Epstein, Audrey Dunn Galvin, Mattia Giovannini, Frédéric Girard, Michael A. Golding, Matthew Greenhawt, Despo Ierodiakonou, Christina J. Jones, Ekaterina Khaleva, Rebecca C. Knibb
-
House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control—A RWE study Allergy (IF 12.4) Pub Date : 2024-03-02 Marek Jutel, Ludger Klimek, Hartmut Richter, Bernd Brüggenjürgen, Christian Vogelberg
-
Persistent sex and race disparities in United States anaphylaxis mortality from 1999 to 2020 Allergy (IF 12.4) Pub Date : 2024-03-02 Ingrid Salciccioli, Padmanabh Bhatt, Joseph Shalhoub, Dominic Marshall, Justin Salciccioli, Kimberly Blumenthal
-
Meta‐analysis in allergy—Statistical recommendations Allergy (IF 12.4) Pub Date : 2024-03-01 Michal Ordak, Giorgio Walter Canonica, Giovanni Paoletti, Liusa Brussino, Daniela Carvalho, Danilo Di Bona
-
Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real‐world data from a single center Allergy (IF 12.4) Pub Date : 2024-03-01 Zijing Yang, Wanting Wen, Ruofei Shi, Lihong Chen, Hailun Wang, Jie Zheng, Haiqin Zhu, Meng Pan, Xiaoqing Zhao
-
Munc13‐4 regulates asthma and obesity in mice by controlling functions of CD11c+ antigen‐presenting cells Allergy (IF 12.4) Pub Date : 2024-03-01 Katsuhide Okunishi, Yuta Kochi, Min Zhao, Hao Wang, Kazuyuki Nakagome, Tetsuro Izumi
Asthma and obesity are both increasing in prevalence globally. Although the causal or pathophysiological relationship between these two diseases is unclear, a significant genetic correlation between these two diseases was recently reported.1 Among the shared disease risk loci, the UNC13D locus is of interest, because this locus has been associated with multiple immune and metabolic traits.2 The risk
-
Immunoglobulin free light chains in severe asthma patient: Could they be a new biomarker? Allergy (IF 12.4) Pub Date : 2024-03-01 C. Caruso, G. Ciasca, I. Baglivo, R. Di Santo, A. Gasbarrini, D. Firinu, D. Bagnasco, G. Passalacqua, M. Schiappoli, M. Caminati, G. W. Canonica, E. Heffler, C. Crimi, R. Intravaia, V. Basile, M. Marino, S. Colantuono, S. Del Giacco
-
Blood basophils and asthma among participants from CONSTANCES, the French population‐based cohort Allergy (IF 12.4) Pub Date : 2024-03-01 Rachel Nadif, Joseph Henny, Tajidine Tsiavia, Céline Ribet, Marcel Goldberg, Marie Zins, Laurent Orsi, Nicolas Roche
Along with eosinophils and neutrophils, basophils have initiator and effector functions in allergy and inflammation.1 However, their role in asthma remains largely unexplored. In adults from CONSTANCES, a population-based cohort, blood inflammatory phenotypes based on eosinophils and neutrophils were associated with distinct clinical expressions of asthma.2 In the present study, we hypothesized that
-
Quality control of allergen products with mass spectrometry part I: Positioning within the EU regulatory framework Allergy (IF 12.4) Pub Date : 2024-03-01 Jelena Spiric, Thomas Schulenborg, Thomas Holzhauser, Frank Schuler, Andreas Bonertz, Iris Lauer, Detlef Bartel, Stefan Vieths, Vera Mahler, Andreas Reuter
Mass spectrometry (MS) has advanced greatly and many of its applications are ready for utilization within regulatory procedures and could significantly contribute to overcome challenges in standardization of allergen products. It seems sensible to discuss MS within the regulatory framework, before addressing technical questions. While the application to purified proteins is well established from product
-
Association between gut microbiota development and allergy in infants born during pandemic-related social distancing restrictions Allergy (IF 12.4) Pub Date : 2024-02-29 Katri Korpela, Sadhbh Hurley, Sinead Ahearn Ford, Ruth Franklin, Susan Byrne, Nonhlanhla Lunjani, Brian Forde, Ujjwal Neogi, Carina Venter, Jens Walter, Jonathan Hourihane, Liam O'Mahony
-
-
-
Mast cell chymase suppresses functional parameters in primary human airway smooth muscle cells Allergy (IF 12.4) Pub Date : 2024-02-27 Xinran O. Zhao, Fabio Rabelo Melo, Christian P. Sommerhoff, Aida Paivandy, Gunnar Pejler
Increased airway smooth muscle cell (SMC) mass is a common feature in asthma development.1, 2 Mast cells (MCs) have an important role in asthma, by releasing various bioactive compounds, including exceptionally large quantities of MC-restricted proteases (e.g., tryptase and chymase). However, the possible functional impact of these proteases on airway SMCs is only partially understood.3 To investigate
-
Correspondence to “intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL‐6‐mediated protection associated with cecal microbiota changes” Allergy (IF 12.4) Pub Date : 2024-02-26 Xin Chen, Yan‐qiu He
-
Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis Allergy (IF 12.4) Pub Date : 2024-02-26 Nan Wang, Jia Song, Shi‐Ran Sun, Ke‐Zhang Zhu, Jing‐Xian Li, Zhi‐Chao Wang, Cui‐Lian Guo, Wen‐Xuan Xiang, Yun‐Long Tong, Ming Zeng, Heng Wang, Xiao‐Yan Xu, Yin Yao, Zheng Liu
-
Impact of air pollutants and meteorological factors on allergic rhinitis outpatient visits in Shanghai, China Allergy (IF 12.4) Pub Date : 2024-02-26 Sun Na, Hao Yanan, Tian Lufang, Sun Zhenfeng, Tang Wei, Huang Yu, Gong Jingrong, Huang Wei, An Kangning, Kan Haidong, Duan Yusen, Yu Shaoqing, Zhang Ruxin